BridgeBio Pharma (NASDAQ:BBIO) executives used the company’s fourth-quarter 2025 earnings call to highlight accelerating ...

Since BridgeBio scored FDA approval for cardiomyopathy drug Attruby 15 | When BridgeBio presented its quarterly report on Tuesday, it laid out expectations on the potential threat of generic pricing ...

- Preliminary unaudited Q4 and Full Year 2025 net Attruby ® product revenue of $146.0 million and $362.4 million, respectively - Attruby (acoramidis) is rapidly becoming the first-choice therapy for ...

The company reiterated its goal of achieving "30-plus percent market share by volume in the years to come" for Attruby. Kumar stated, "The obvious growth in our portfolio today sits with the expansion ...

- As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR ...

No-moat BridgeBio reported fourth-quarter results that were largely in line with our expectations. Investors have reacted positively to BridgeBio’s recent developments and have sent the stock up 30% ...

Management expects cash burn to hold steady through 2026 and start declining by the end of next year, driven by increasing Attruby revenues and improved operating leverage. Kumar said, "Our current ...

- Attruby (acoramidis) is rapidly becoming the first-choice therapy for newly diagnosed ATTR-CM patients with 6,629 unique patient prescriptions written by 1,632 prescribers as of December 31, 2025, ...